Citations

Showing 10 of 108094 citations.

Eosinophilic Disorders of the Gastrointestinal Tract and Associated Abdominal Viscera: Imaging Findings and Diagnosis
Yalon, Mariana , Amawi, Ali Dean Tahboub , Kelm, Zachary S. , Wells, Michael , Teo, Lynette , Heiken, Jay P. , Sheedy, Shannon P. , Torbenson, Michael , Fidler, Jeff L. , Venkatesh, Sudhakar K. , Tahboub Amawi, Ali D , Wells, Michael L , Teo, Lynette L S , Torbenson, Michael S , Venkatesh, Sudhakar K , Yalon, Mariana , Fidler, Jeff L.

Mayo Clinic

RadioGraphics | June 24, 2022 | Volume: 42 | Issue: 4 | Pages: 1081-1102

10.1148/rg.220004 | PMID 35749291 Get It

Procedural learning, declarative learning, and working memory as predictors of learning the use of a memory compensation tool in persons with amnestic mild cognitive impairment
Wit, Liselotte De , Levy, Shellie‐Anne , Amofa, Priscilla , DeFeis, Brittany , O’Shea, Deirdre , Chandler, Melanie , De Wit, Liselotte , Chandler, Melanie J, Kurasz, Andrea M. , Smith, Glenn E.

Mayo Clinic

Neuropsychological Rehabilitation | June 24, 2022 | Volume: 33 | Issue: 7 | Pages: 1278-1303

10.1080/09602011.2022.2089697 | PMID 35749375 Get It

Hyperbaric effects on cold stored whole blood following a military dive mission profile
Scheiber, Christopher , Spencer, Chad M., Neading, Richard D., Becker, C, Scarborough, Tyler R., Horsey, Jeremy D., Perez, Joshua A., Ochoa, Baron J., Bentley, Pasha, Seheult, Jansen N. , Yazer, Mark H. , Scheiber, Christopher J , Seheult, Jansen N , Boisen, Michael L , Yazer, Mark H , Neading, Richard, O'Connell, Michael P., Scarborough, Tyler, Wilkinson, Michael A.

Mayo Clinic

Transfusion | June 24, 2022 | Volume: 62 | Issue: S1 | Pages: No page available

10.1111/trf.16963 | PMID 35748679 Get It

AbstractBackgroundWhole blood (WB) is carried by special operations forces as part of a remote damage control resuscitation strategy. The effects of an underwater mission on the quality and coagulation profile of WB were simulated by exposure to hyperbaric pressures in a chamber.MethodsWB units collected in CPDA‐1 were exposed to three different combinations of hyperbaric pressure and duration of exposure: Group A 153.52 kPa (15.24 msw; 1.52 atm) for 4 h; n = 9, Group B 506.63 kPa (50.29 msw; 5.00 atm) for 1 h; n = 9, Group C 153.52 kPa (15.24 msw; 1.52 atm) for 1 h; n = 7. The following parameters were measured on each unit: prothrombin time/international normalized ratio, activated partial thromboplastin time, thromboelastography and concentration determinations of platelets, lactate, fibrinogen, and lactate dehydrogenase. Each sample underwent baseline, prepressurization, immediate postpressurization, and 6 h postpressurization laboratory testing.ResultsSix hours following hyperbaric exposure, the lactate concentration in group C was higher than prepressurization measurement and the platelet concentration in Group A was lower than prepressurization measurement. There were no changes in any of the other analyzed biochemical, coagulation and thromboelastogram parameters following exposure to hyperbaric stress.DiscussionThese data suggest that pressurization of WB up to 5 atm did not impact parameters tested. Changes observed in lactate and platelet count need further study, as well as complementary testing of red blood cell integrity. Further investigation of the hyperbaric extremes is necessary to determine if there is a damage inducing pressure to which WB should not be exposed.
Opinions on noninvasive sensory feedback of upper limb prosthetic users
Smither, F. Clay , Andrews, Karen L., Scrabeck, Tyson L., Lennon, Ryan J. , Zhao, Kristin D. , Trentadue, Taylor P

Mayo Clinic

Prosthetics & Orthotics International | June 24, 2022 | Volume: 46 | Issue: 6 | Pages: 591-600

10.1097/pxr.0000000000000160 | PMID 36515904 Get It

Background: Restoring touch perception for individuals with upper extremity limb loss is an ambitious task. It is important to understand how persons with upper limb loss think this would be best achieved. Methods: An anonymous online survey was developed to obtain data from prosthetic users. Participants ranked the perceived acceptability and effectiveness of noninvasive sensory feedback to areas of intact sensation not typically involved in sensory feedback (i.e., the arm). The focus was on 4 main types of haptic information—object contact, proprioception, surface texture, and grasp force—as well as how best to convey those senses with various stimuli. The users were asked to grade themselves in certain tasks and then analyze which tasks would be improved with sensory feedback. Associations were explored between demographic characteristics and interest in sensory feedback. Results: Nationally, prostheses providers sent more than 2000 email invitations to the online survey and received 142 unique responses. Responses indicated interest in sensory feedback through prosthetic limbs by individuals with upper limb loss. The most popular pairing of haptic information with sensory substitution was grasp force paired with gentle vibration. Tasks that most persons taking the survey agreed would benefit from sensory feedback were zipping a jacket, tying shoes, buttoning a shirt, and using a cup. No difference was observed in interest between sex and employment status, but a significant decrease (P = .004) was seen in interest among participants with more years of prosthetic use. Discussion: The results from this national survey of upper extremity prosthetic users can be used to help guide the development of noninvasive sensory feedback options.
Comparative risk of pulmonary adverse events with transfusion of pathogen reduced and conventional platelet components
Snyder, Edward L. , Wheeler, Allison P. , Refaai, Majed A. , Cohn, Claudia S. , Poisson, Jessica , Fontaine, Magali J. , Sehl, Mary E. , Uhl, Lynne , Spinella, Philip C. , Fenelus, Maly , Coyle, Thomas, Becker, Joanne , Jeng, Michael , Spencer, Bryan R. , Young, Pampee P. , OʼBrien, Jennifer , Schiller, Gary J. , Roback, John D. , Malynn, Elizabeth, Jackups, Ronald , Avecilla, Scott T. , Lin, Jin‐Sying, Bentow, Stanley, Peng, Ho‐Lan, Varrone, Jeanne, Fontaine, Magali , Spinella, Philip C , Gehrie, Eric A , Spencer, Bryan R , Young, Pampee , O'Brien, Jennifer J, Avecilla, Scott T , Benjamin, Richard J , Corash, Laurence M , Cohn, Claudia S , Wheeler, Allison P , Jeng, Michael , Nooka, Ajay K. , Liles, Darla , Johnson, Andrew, Liu, Kathy

Mayo Clinic

Transfusion | June 24, 2022 | Volume: 62 | Issue: 7 | Pages: 1365-1376

10.1111/trf.16987 | PMID 35748490 Get It

AbstractBackgroundPlatelet transfusion carries risk of transfusion‐transmitted infection (TTI). Pathogen reduction of platelet components (PRPC) is designed to reduce TTI. Pulmonary adverse events (AEs), including transfusion‐related acute lung injury and acute respiratory distress syndrome (ARDS) occur with platelet transfusion.Study designAn open label, sequential cohort study of transfusion‐dependent hematology‐oncology patients was conducted to compare pulmonary safety of PRPC with conventional PC (CPC). The primary outcome was the incidence of treatment‐emergent assisted mechanical ventilation (TEAMV) by non‐inferiority. Secondary outcomes included: time to TEAMV, ARDS, pulmonary AEs, peri‐transfusion AE, hemorrhagic AE, transfusion reactions (TRs), PC and red blood cell (RBC) use, and mortality.ResultsBy modified intent‐to‐treat (mITT), 1068 patients received 5277 PRPC and 1223 patients received 5487 CPC. The cohorts had similar demographics, primary disease, and primary therapy. PRPC were non‐inferior to CPC for TEAMV (treatment difference −1.7%, 95% CI: (−3.3% to −0.1%); odds ratio = 0.53, 95% CI: (0.30, 0.94). The cumulative incidence of TEAMV for PRPC (2.9%) was significantly less than CPC (4.6%, p = .039). The incidence of ARDS was less, but not significantly different, for PRPC (1.0% vs. 1.8%, p = .151; odds ratio = 0.57, 95% CI: (0.27, 1.18). AE, pulmonary AE, and mortality were not different between cohorts. TRs were similar for PRPC and CPC (8.3% vs. 9.7%, p = .256); and allergic TR were significantly less with PRPC (p = .006). PC and RBC use were not increased with PRPC.DiscussionPRPC demonstrated reduced TEAMV with no excess treatment‐related pulmonary morbidity.
Preoperative hemoglobin A1c and perioperative blood glucose in patients with diabetes mellitus undergoing spinal cord stimulation surgery: A literature review of surgical site infection risk
Hagedorn, Jonathan M. , Bendel, Markus A. , Hoelzer, Bryan C. , Aiyer, Rohit , Caraway, David , Hagedorn, Jonathan M

Mayo Clinic

Pain Practice | June 24, 2022 | Volume: 23 | Issue: 1 | Pages: 83-93

10.1111/papr.13145 | PMID 35748888 Get It

Abstract Aims The aim of our study was to review the surgical literature regarding the relationship between hemoglobin A1c (HbA1c), diagnosis of diabetes mellitus (DM), and risk of postoperative surgical site infection (SSI). Methods A librarian‐assisted literature search was performed with two goals: (1) identify surgical publications related to SSI and HbA1c values, and (2) identify publications reporting infection risk with DM in spinal cord stimulation (SCS), intrathecal drug delivery systems (IDDS), and cardiovascular implantable electronic device (CIED) implantation surgeries. Published guidelines on perioperative management of DM are reviewed. Results We identified 30 studies reporting SSI and HbA1c values. The literature review indicated that for many surgical procedures, elevated HbA1c is not correlated to rate of SSI. We identified 16 studies reporting infection rates within DM cohorts following SCS, IDDS, and CIED implantation surgeries. The data reviewed did not indicate DM as an independent risk factor for SSI. Conclusion Preoperative HbA1c levels in patients with a history of DM is not a singularly sufficient tool to estimate risk of perioperative infection in SCS implantation surgery. Published guidelines on perioperative management of DM do not suggest a specific HbA1c above which surgery should be delayed; intentional perioperative glycemic control is recommended.
Nivolumab in patients with relapsed or refractory peripheral T-cell lymphoma: modest activity and cases of hyperprogression
Bennani, N. Nora , Pederson, Levi , Atherton, Pamela J. , Micallef, Ivana N. , Thanarajasingam, Gita , Nowakowski, Grzegorz S. , Ansell, Stephen M. , Bennani, N Nora , Kim, Hyo Jin , Witzig, Thomas E. , Feldman, Andrew L.

Mayo Clinic

Journal for ImmunoTherapy of Cancer | June 24, 2022 | Volume: 10 | Issue: 6 | Pages: e004984

10.1136/jitc-2022-004984 | PMID 35750419 Get It

Peripheral T-cell lymphomas (PTCL), a heterogeneous group of mature aggressive non-Hodgkin’s lymphomas, carry a worse prognosis for most subtypes when compared with their B-cell counterparts. Despite recent approval of newer therapies, the outlook for patients with relapsed/refractory (RR) PTCL remains poor and new treatment strategies are clearly needed. Targeting the profoundly immunosuppressive tumor microenvironment in PTCL is one such approach. To determine whether immune checkpoint blockade targeting program death receptor 1 would be effective in PTCL, we conducted an investigator-initiated phase 2 prospective study of single-agent nivolumab for RR PTCL. We report here results of the pre-specified interim analysis. Methods The primary objective was to assess the overall response rate (ORR). Secondary objectives were to assess safety and tolerability of nivolumab in PTCL and to assess progression-free survival (PFS), duration of response (DOR) and overall survival (OS). Hyperprogressive disease (HPD) was defined as time-to-treatment failure of less than or equal to one month from initiation of therapy. Results Twelve patients who received at least one cycle of nivolumab were included in this interim analysis. Half (6/12) of the patients had angioimmunoblastic T-cell lymphoma (AITL), 3/12 had PTCL, not otherwise specified. Most (11/12) were advanced stage, had extranodal disease (97.1%) and had received a prior autologous stem cell transplant (50%). The ORR was 33% (95% CI: 12.3 to 63.7%) with two complete response and two partial response. The median PFS was however short at 2.7 months (95% CI: 1.5 to NE); and the median OS was 6.7 months (95% CI: 3.4 to NE). The median DOR was also short at 3.6 months (95% CI: 1.9 to NE). HPD occurred in four patients, three of whom had AITL. Observed grade 3 and higher adverse events (AEs) were non-hematologic in 5/12 (42%), while hematologic AEs were seen in 3/12 (25%). Conclusions Nivolumab had modest clinical activity in R/R PTCL. Due to a high number of hyperprogression and short DOR, a decision was made to halt the study. These findings likely reflect the distinct biology of PTCL and should be considered when designing future studies using checkpoint inhibitors in these diseases. Trial registration number NCT03075553.
PB1878: CROSS-TRIAL ANALYSIS OF FIXED-DURATION IBRUTINIB (I) PLUS VENETOCLAX (V) VS FLUDARABINE (F), CYCLOPHOSPHAMIDE (C), AND RITUXIMAB (R) AS FIRST-LINE TREATMENT FOR CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)
Mato, Anthony R. , Moreno, Carol , Szafer‐Glusman, Edith , Zhou, Cathy , Neumayr, Lynne , Krigsfeld, Gabriel , Barrientos, Jacqueline C. , Barr, Paul M. , Tam, Constantine S. , Ghia, Paolo , Kay, Neil E. , Siddiqi, Tanya , Wierda, William G. , Shanafelt, Tait D.

Mayo Clinic

HemaSphere | June 24, 2022 | Volume: 6 | Issue: No issue available | Pages: 1758-1759

10.1097/01.hs9.0000850364.78915.d9 Get It

PB1887: NETWORK META-ANALYSIS OF PROGRESSION FREE SURVIVAL IN THE TREATMENT OF RELAPSED OR REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA
Chanan‐Khan, Asher , Liu, T., Yang, Kaiqian, Cohen, A., Fahrbach, Kyle , Campbell, Joanna, Tang, B., Liu, T., Tang, B

Mayo Clinic

HemaSphere | June 24, 2022 | Volume: 6 | Issue: No issue available | Pages: 1766-1767

10.1097/01.hs9.0000850400.19760.77 Get It

PB2003: REAL-WORLD DURATION OF USE AND DOSING FREQUENCY OF DARATUMUMAB IN PATIENTS WITH MULTIPLE MYELOMA IN THE U.S.
Chinaeke, E., Gupta, Niodita, Fu, Alex Z. , Ran, T., Kaila, S., Fonseca, Rodrigo , Ran, T.

Mayo Clinic

HemaSphere | June 24, 2022 | Volume: 6 | Issue: No issue available | Pages: 1874-1875

10.1097/01.hs9.0000850844.58786.ec Get It